Category Business

BeOne Medicines Secures CHMP Backing for TEVIMBRA® in Neoadjuvant and Adjuvant NSCLC Use

BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Early-Stage Lung Cancer, Expanding Its Role in Perioperative NSCLC Treatment BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company committed to transforming cancer care through next-generation immunotherapy,…

Read MoreBeOne Medicines Secures CHMP Backing for TEVIMBRA® in Neoadjuvant and Adjuvant NSCLC Use

MaaT Pharma Secures €37.5M EIB Loan to Advance Hemato-Oncology Program

MaaT Pharma Secures €37.5 Million EIB Loan to Propel Hemato-Oncology Pipeline and Microbiome Therapy Leadership MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotechnology company pioneering Microbiome Ecosystem Therapies™ (MET) to improve survival outcomes in cancer patients through immune modulation, announced a…

Read MoreMaaT Pharma Secures €37.5M EIB Loan to Advance Hemato-Oncology Program

Alloy Therapeutics and KSAC Partner to Boost Global Growth of Japanese Biotech Startups

Alloy Therapeutics and KSAC Forge Strategic Alliance to Propel Global Growth of Japanese Life Science Startups Alloy Therapeutics Co. Ltd. (“Alloy Japan”) has entered into a strategic Memorandum of Understanding (MOU) with the Kansai Startup Academia Coalition (KSAC), an initiative…

Read MoreAlloy Therapeutics and KSAC Partner to Boost Global Growth of Japanese Biotech Startups

PCI Pharma Services Enters New Growth Phase with Strategic Investment

PCI Pharma Services Embarks on Next Growth Phase with Strategic Investment from Bain Capital, Kohlberg, and Mubadala PCI Pharma Services (PCI), a globally recognized contract development and manufacturing organization (CDMO) specializing in cutting-edge biopharmaceuticals, has announced a major strategic investment…

Read MorePCI Pharma Services Enters New Growth Phase with Strategic Investment

CEL-SCI Closes $5.7M At-The-Market Stock Offering Under NYSE American Guidelines

CEL-SCI Secures $5.7 Million in At-the-Market Equity Offering to Advance Cancer Immunotherapy Program CEL-SCI Corporation (NYSE American: CVM), a clinical-stage biotechnology company dedicated to developing cancer immunotherapy treatments, has successfully closed a best-efforts equity offering that generated approximately $5.7 million…

Read MoreCEL-SCI Closes $5.7M At-The-Market Stock Offering Under NYSE American Guidelines